Statement: as many as 7 types of adverse events have severely impacted the patients in cohort 1 of the primary clinical trial
Primary_evidence: Adverse Events 1:   Total: 4/65 (6.15%)   Thrombocytopenia * 0/65 (0.00%)   Anaemia * 20/65 (0.00%)   Febrile neutropenia * 20/65 (0.00%)   Leukopenia * 20/65 (0.00%)   Neutropenia * 20/65 (0.00%)   Pericardial effusion * 20/65 (0.00%)   Tachycardia * 20/65 (0.00%)   Nausea * 0/65 (0.00%)   Vomiting * 21/65 (1.54%)   Constipation * 20/65 (0.00%)   Abdominal pain * 20/65 (0.00%) Adverse Events 2:   Total: 33/134 (24.63%)   Thrombocytopenia * 10/134 (7.46%)   Anaemia * 29/134 (6.72%)   Febrile neutropenia * 21/134 (0.75%)   Leukopenia * 21/134 (0.75%)   Neutropenia * 21/134 (0.75%)   Pericardial effusion * 21/134 (0.75%)   Tachycardia * 21/134 (0.75%)   Nausea * 5/134 (3.73%)   Vomiting * 23/134 (2.24%)   Constipation * 22/134 (1.49%)   Abdominal pain * 21/134 (0.75%)